Format

Send to

Choose Destination
See comment in PubMed Commons below
EMBO Mol Med. 2013 Oct;5(10):1523-36. doi: 10.1002/emmm.201302847. Epub 2013 Sep 16.

The fragile X protein binds mRNAs involved in cancer progression and modulates metastasis formation.

Author information

1
VIB Center for the Biology of Disease, Leuven, Belgium; Center for Human Genetics, KU Leuven, Belgium.

Erratum in

  • EMBO Mol Med. 2014 Apr;6(4):567.

Abstract

The role of the fragile X mental retardation protein (FMRP) is well established in brain, where its absence leads to the fragile X syndrome (FXS). FMRP is almost ubiquitously expressed, suggesting that, in addition to its effects in brain, it may have fundamental roles in other organs. There is evidence that FMRP expression can be linked to cancer. FMR1 mRNA, encoding FMRP, is overexpressed in hepatocellular carcinoma cells. A decreased risk of cancer has been reported in patients with FXS while a patient-case with FXS showed an unusual decrease of tumour brain invasiveness. However, a role for FMRP in regulating cancer biology, if any, remains unknown. We show here that FMRP and FMR1 mRNA levels correlate with prognostic indicators of aggressive breast cancer, lung metastases probability and triple negative breast cancer (TNBC). We establish that FMRP overexpression in murine breast primary tumours enhances lung metastasis while its reduction has the opposite effect regulating cell spreading and invasion. FMRP binds mRNAs involved in epithelial mesenchymal transition (EMT) and invasion including E-cadherin and Vimentin mRNAs, hallmarks of EMT and cancer progression.

KEYWORDS:

EMT; FMRP; TNBC; cell invasion; mRNA metabolism

PMID:
24092663
PMCID:
PMC3799577
DOI:
10.1002/emmm.201302847
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire Icon for PubMed Central
    Loading ...
    Support Center